| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | 30.3 | 76.3 |
| Profit before tax | 3.3 | 56.6 |
| Net income | 3.9 | 15.1 |
| EPS (diluted, $ a share) | $0.11 | $0.52 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -74.4% |
|---|---|
| Revenue, year on year | -60.3% |
| Operating margin | 65.7% |
10-Q filed with the SEC, NASDAQ: ANAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Anaptysbio, Inc: key numbers
- Share price
- $45.73Close, Nov 16
- Market cap
- $1.37B
- Shares outstanding
- 29.9MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Anaptysbio, Inc
All →Anaptysbio Financial Results
AnaptysBio reported financial results for the fiscal first quarter ended September 30, 2026, highlighted by $1.0 billion in global net sales of Jemperli for the first nine months of 2026. The company is currently awaiting a court judgment in its litigation against GSK and Tesaro, where it is seeking the reversion of Jemperli rights as a remedy.
- Counterparty
- GSK
“Jemperli’s continued commercial growth in endometrial cancer, with global net sales reaching $1 billion through September 30, 2026, and its recent U.S. approval in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer reinforce our confidence in its long-term potential in monotherapy indications.”
Daniel Faga, president and chief executive officer
“We remain focused on protecting and returning the value of our financial collaborations to shareholders as we approach a judgment in our litigation with GSK and Tesaro in calendar Q4 2026 or Q1 2027 and the FDA target action date for Quimilza in December 2026.”
Daniel Faga, president and chief executive officer
Anaptysbio Director Hollings Renton Sells $249K of Stock
Hollings Renton, Director, sold 5,000 shares of Anaptysbio, Inc at $49.87 a share, worth $249K in total on Oct 1, 2026. Shares held after the trade: 10,995 (-31.3%).
- Value
- $249K
- Shares
- 5,000
- Price
- $49.87
- Role
- Director
- Holding change
- -31.3%
- Trade date
- Oct 1, 2026
Anaptysbio Financial Results
AnaptysBio reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, highlighted by $644 million in global net sales for Jemperli, representing 34% year-over-year growth. The company is awaiting a court judgment in its litigation with GSK and Tesaro expected by Q1 2027 and anticipates FDA approval for Quimilza in December 2026.
- Counterparty
- GSK
- Term
- Q2 2026
“Jemperli continues to demonstrate robust year-over-year growth with major catalysts within the next 6 months including further sales acceleration ex-US, anticipated FDA approval of Jemperli in monotherapy in dMMR/MSI-H neoadjuvant rectal cancer, as well as a judgement expected in our litigation with GSK and Tesaro.”
Daniel Faga, president and chief executive officer